PARSIPPANY, New Jersey and TEL AVIV, Israel, May 17, 2016 /PRNewswire/ -- Medinol announced outstanding results from the NIREUS trial for BioNIR(TM), its new coronary stent system and the first ever elastomeric Drug Eluting Stent or eDES(TM). NIREUS is a prospective, multi center, randomized, non-inferiority pivotal study comparing Medinol's BioNIR to the Resolute Integrity(TM) Stent. The study enrolled 302 patients with coronary artery disease at 31 sites in Europe and Israel and will be used to support Medinol's submission for CE mark.
Logo - http://photos.prnewswire.com/prnh/20150922/269421LOGO [http://photos.prnewswire.com/prnh/20150922/269421LOGO]
NIREUS met its non-inferiority primary end point of angiographic in-stent late loss at 6 months. The BioNIR stent has demonstrated an exceptionally low late loss result of 0.04+/-0.31 mm (N=201) compared with 0.03+/-0.31 mm for Resolute Integrity (N=101) with a high degree of statistical significance (p